Abstract: Approximately all low-risk gestational trophoblastic neoplasia (LR-GTN) can be cured by chemotherapy. After first single-agent treatment 10 to 67 percent of patients become drug resistant, while 1.3 to 8.3 percent relapse, which not only brings heavy load to their economy, but also casts dark shadow physically and psychologically. Experts from home and abroad have paid more and more attention to this issue, with the expectation of improving prognosis through adequate clinical interventions at an early stage of the disease. Researches have manifested different possible related factors, certain experience been learned, such as some items within the FIGO system, FIGO total score and others including β-hCG modeled residual production (hCGres), uterine artery pulsatility index (UAPI), certain image changes of lesions through TVS, choriocacinoma, consolidation course number and drugs and regimens chosen, but they are still controversial. The current knowledge about risk factors associated with resistance and recurrence in LR-GTN cases after initial single chemotherapy was reviewed.

Key words: Gestational trophoblastic neoplasms, Drug therapy, combination, Drug resistance, neoplasm, Recurrence, Gestational trophoblastic neoplasms, Drug therapy, combination, Drug resistance, neoplasm, Recurrence, Risk factors